Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Clene Inc (NQ: CLNN )

0.3349 -0.0116 (-3.35%)
Streaming Delayed Price Updated: 1:05 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 55,192
Open 0.3465
Bid (Size) 0.3305 (4)
Ask (Size) 0.3349 (3)
Prev. Close 0.3465
Today's Range 0.3301 - 0.3500
52wk Range 0.2500 - 1.090
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Clene Inc. (NASDAQ: CLNN) Continues Development of Lead Drug Candidate CNM Au8(R) for Neurodegenerative Diseases including Parkinson’s Disease
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga

Performance

YTD
+13.91%
+13.91%
1 Month
-21.03%
-21.03%
3 Month
-36.80%
-36.80%
6 Month
-20.26%
-20.26%
1 Year
-64.76%
-64.76%

More News

Read More
The Analyst Verdict: Clene In The Eyes Of 5 Experts
Via Benzinga
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Study Results for CNM-Au8 as Multiple Sclerosis Treatment Presented at AAN Conference
Via Investor Brand Network
Breaking Down Clene: 4 Analysts Share Their Views
Via Benzinga
Clene: Q4 Earnings Insights
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Why INVO Bioscience Shares Are Trading Higher By Around 73%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Study Identifies Three Distinct Subtypes of Multiple Sclerosis
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Looking to Advance Discussions for Accelerated Approval, New NDA for CNM-Au8(R) in 2024
Via Investor Brand Network
Exposures Product Safety
Clene Inc. (NASDAQ: CLNN) has Emerged as a Leader in the Neurodegenerative Field Utilizing a Novel Nanotherapeutic Drug
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Announces Publication of “Protein Corona Composition of Gold Nanocatalysts” in ACS Pharmacology & Translational Science
Via Investor Brand Network
3 Penny Stocks That Could Be Multibaggers in the Making: March Edition
Via InvestorPlace
Clene Inc. (NASDAQ: CLNN) Announces Operational Highlights for Lead Therapeutic Candidate for ALS and MS
Via Investor Brand Network
New Study Leverages Real-World Data to Assess Differences in Parkinson’s Progression
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) Work in Nanotechnology Highlighted in ‘First in Human’ Podcast
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Publication of Peer-Reviewed Research for Investigational Drug CNM-Au8(R)
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces FY 2023 Results, Recent Operating Highlights
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Participation at Upcoming 36th Annual Roth Conference
Via Investor Brand Network
A Comparison Between ALS, Parkinson’s Disease
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN), Subsidiary Report Positive Clinical Results of CNM-Au8 Treatment at MS Forum
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc.’s (NASDAQ: CLNN) CNM-Au8 Aiming to Address Neurodegenerative Diseases from a New Angle
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Statistically Significant Results from Independent Analyses of ALS Patient Data
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.